Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 17,037

Document Document Title
WO/2014/111580A1
A composition comprising a sufficient amount of urolithin B or a derivative thereof, for increasing muscle cell size.  
WO/2014/110291A1
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and d...  
WO/2014/106473A1
Disclosed is use of glycyrrhetinic acid or glycyrrhizic acid in preventing or treating radiation injury of soft tissue. Therefore, glycyrrhetinic acid or glycyrrhizic acid can be used for preparing medicaments for preventing or treating ...  
WO/2014/107566A1
Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury such as trauma.  
WO/2014/103410A1
An IGF-1 production promoter comprises, as an active ingredient: a Citrus depressa Hayata extract, preferably water and/or organic solvent extract of Citrus depressa Hayata fruit or leaves, a supercritical extract of Citrus depressa Haya...  
WO/2014/099904A1
Methods for enhancing motor function, enhancing functional status, and mitigating muscle weakness in a subject are provided. The methods utilize the combination of administering to the subject a nutritional composition comprising at leas...  
WO/2014/098249A1
The purpose of the present invention is to provide a composition having a tissue repairing activity that is capable of promoting a reaction relating to tissue repairing. Disclosed is a composition having an activity of repairing a tissue...  
WO/2014/089913A1
The present invention relates to a compound shown in a formula (I), a method for preparing the compound, a pharmaceutical composition containing the compound, and applications of the compound in preparing drugs for preventing and/or trea...  
WO/2014/092150A1
A peptide or pharmaceutically acceptable salt thereof selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly, and Pro-Hyp having more excellent myoblast differentiation acceleratio...  
WO/2014/091446A1
The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.  
WO/2014/091020A1
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...  
WO/2014/088106A1
A substance capable of binding to mSin3B, said substance exhibiting an analgesic effect on an ICS (intermittent cold stress) mouse, which is an experimental animal model of fibromyalgia, and, therefore, being useful as a prophylactic or ...  
WO/2014/086243A1
Disclosed are a miRNA molecule for negatively regulating a type I interferon pathway and uses thereof, discovering that Has-miR-127-3p is closely related to systemic lupus erythematosus, and also verifying the target pathway of the miRNA...  
WO/2014/089268A3
Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.  
WO/2014/086687A1
The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic ...  
WO/2014/087298A1
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/087298A4
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/084434A1
To prevent and treat a rotator cuff injury, the present invention provides a composition for preventing and treating a rotator cuff injury, containing cyanidin or delphinidin as an active ingredient.  
WO/2014/080286A3
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanopartic...  
WO/2014/075135A1
The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceuticall...  
WO/2014/066964A1
The present Certificate of Addition relates to the use of pharmaceutical compositions containing a Mas receptor agonist, such as Angiotensin-(1-7), for treating degenerative muscular diseases.  
WO/2014/071168A3
Methods and compositions useful for reducing loss of muscle function caused by bone metastasis in a subject with cancer. In certain embodiments, the methods of the present invention include administering to a cancer patient compositions ...  
WO/2014/071131A1
The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.  
WO/2014/065413A1
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/063602A1
Disclosed is a drug targeting delivery adjuvant, which is at least one selected from the group of pentoses selected from xylose and arabinose; hexoses selected from glucose, galactose, fructose and mannose; sugar alcohols selected from s...  
WO/2014/065341A1
The present invent addresses the problem of providing a medicine for treating amyotrophic lateral sclerosis, a disease for which there is currently no effective therapeutic agent, and provides a therapeutic agent for amyotrophic lateral ...  
WO/2014/059403A1
Described herein are chimeric proteins, pharmaceutical compositions and methods for treating organophosphate exposure and poisoning (e.g., nerve agent poisoning, pesticide poisoning) in a subject (e.g., a human subject) and preventing or...  
WO/2014/059013A1
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e...  
WO/2014/058000A1
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/054635A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/055905A1
Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate ("EGCg") in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, th...  
WO/2014/054634A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/053857A1
Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. Th...  
WO/2014/050779A1
To provide a combination therapy for cancer, which comprises a combination of a GSK3 inhibitor and an anti-DR5 antibody. Provided are a pharmaceutical product and a combination therapy, each of which comprises a combination of various an...  
WO/2014/051398A1
The present invention relates to a composition for promoting differentiation of myoblast, comprising Acecainide or Procainamide which is a derivative of Acecainide, or pharmaceutically acceptable salts of Acecainide, to a method for prom...  
WO/2014/049841A1
The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clar...  
WO/2014/048071A1
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/046065A1
Provided is a material that, as a myocardial/cardiovascular regeneration device, is for the treatment of advanced heart failure, and with respect to the fundamental treatment of intractable circulatory diseases regarding which not only s...  
WO/2014/047497A1
Disclosed are nutritional compositions, and methods of using and making the nutritional compositions, that include calcium beta-hydroxy-beta-methylbutyrate and protein. The calcium beta-hydroxy-beta-methylbutyrate is in sequestered or io...  
WO/2014/042981A3
This document provides methods and materials for treating digital ulcers, pulmonary arterial hypertension, vasculitis conditions, inflammatory myositis conditions, or combinations thereof. For example, methods and materials involved in u...  
WO/2014/043696A3
The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatm...  
WO/2014/038623A1
Provided is a therapeutic agent for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated ...  
WO/2014/039916A1
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Gi...  
WO/2014/039920A1
Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood ...  
WO/2014/040077A1
Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a s...  
WO/2014/033654A1
The present invention provides a compound of formula (I) in acetate salt form (I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacological...  
WO/2014/034756A1
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/030624A1
Disclosed are: a therapeutic agent for myotonic dystrophy, particularly myotonic dystrophy associated with impaired glucose tolerance or diabetes; and a therapeutic agent for impaired glucose tolerance or diabetes each associated with my...  
WO/2014/030514A1
The present invention addresses the problem of providing a muscle atrophy inhibitor that is efficacious for disuse muscle atrophy and age-related muscle atrophy and easy to use. The muscle atrophy inhibitor comprises, as an active ingred...  
WO/2014/026330A1
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  

Matches 101 - 150 out of 17,037